Ipsen’s Cabometyx wins EU nod for liver cancer
Ipsen’s Cabometyx can now be used as monotherapy to treat certain patients with liver cancer following a green light from regulators in Europe.
Read Moreby Selina McKee | Nov 15, 2018 | News | 0
Ipsen’s Cabometyx can now be used as monotherapy to treat certain patients with liver cancer following a green light from regulators in Europe.
Read Moreby Selina McKee | Oct 31, 2018 | News | 0
NICE has published draft guidelines rejecting Sanofi Genzyme’s Caprelsa for treating medullary thyroid cancer (MTC) that cannot be operated on or has spread around the body.
Read Moreby Selina McKee | Mar 28, 2018 | News | 0
Ipsen’s Cometriq can now be routinely funded by the NHS to treat patients with medullary thyroid cancer (MTC) in England and Wales.
Read Moreby Selina McKee | Aug 23, 2017 | News | 0
It is looking likely that patients in England will loose NHS access to Ipsen’s Cometriq and Sanofi Genzyme’s Caprelsa via the Cancer Drugs Fund, after cost-regulators turned down funding for their use.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
